Biogen

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,500

Employees7,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,500

Employees7,500

BIIB Key Statistics

Market cap

31.40B

Market cap31.40B

Price-Earnings ratio

23.19

Price-Earnings ratio23.19

Dividend yield

—

Dividend yield—

Average volume

1.42M

Average volume1.42M

High today

$215.95

High today$215.95

Low today

$209.27

Low today$209.27

Open price

$215.95

Open price$215.95

Volume

481.25K

Volume481.25K

52 Week high

$219.72

52 Week high$219.72

52 Week low

$121.05

52 Week low$121.05

Stock Snapshot

With a market cap of 31.4B, Biogen(BIIB) trades at $212.70. The stock has a price-to-earnings ratio of 23.19.

On 2026-07-06, Biogen(BIIB) stock traded between a low of $209.27 and a high of $215.95. Shares are currently priced at $212.70, which is +1.6% above the low and -1.5% below the high.

Biogen(BIIB) shares are trading with a volume of 481.25K, against a daily average of 1.42M.

In the last year, Biogen(BIIB) shares hit a 52-week high of $219.72 and a 52-week low of $121.05.

BIIB News

TipRanks 4h

Biogen price target raised to $157 from $150 at HSBC

HSBC analyst Morten Herholdt raised the firm’s price target on Biogen (BIIB) to $157 from $150 and keeps a Reduce rating on the shares. In a sector note on Heal...

Simply Wall St 7h

How AAIC 2026 Alzheimer’s Data Releases Could Reframe Biogen Investors’ Long‑Term Thesis

In late June 2026, Biogen announced it would present new clinical, biomarker and safety data from its Alzheimer’s portfolio at AAIC 2026 in London, including Ph...

Simply Wall St 2d

Biogen Could Be 1% Undervalued Before Key AAIC Alzheimer’s Data

Advertisement Why Biogen’s AAIC 2026 data drop matters for the stock Biogen (BIIB) is in focus as it prepares to share detailed diranersen Phase 2 results and...

Analyst ratings

58%

of 38 ratings

Buy

57.9%

Hold

36.8%

Sell

5.3%

More BIIB News

The Motley Fool 2d

Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.

Biogen (BIIB +3.04%) built itself into a biotech giant thanks to its portfolio of multiple sclerosis (MS) drugs -- but in biotech and pharma, revenue growth dep...

Simply Wall St 4d

Biogen Stock Looks Near Fair Value After A 57% Run

Biogen stock has delivered a strong 57.5% return over the past year, yet the broader valuation checks suggest the shares now look closer to fairly priced than c...

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.